nach oben

Clinical and Translational Oncology

Erschienen in:

16.06.2017 | Review article

Pancreatic ductal adenocarcinoma: metastatic disease

verfasst von: A. J. Muñoz Martín, J. Adeva, J. Martínez-Galán, J. J. Reina, M. Hidalgo

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called “therapeutic sequencing” has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient’s characteristics.

http://seer.cancer.gov/statfacts/html/pancreas.html, Accessed Feb 2016.

Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr J, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8–18.CrossRefPubMed

Sener SF, Fremgen A, Menck HR, Winchester D. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1–7.CrossRefPubMed

Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–44.CrossRefPubMed

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef

Peixoto RD, Ho M, Renouf DJ, Lim HJ, Gill S, Ruan JY, et al. Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol. 2015. doi:10.1097/COC.0000000000000193.

Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park). 2014;28:70–4.

Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5:3–29.CrossRefPubMedPubMedCentral

10.

Chen YG, Pan HH, Dai MS, Kin C, Lu CS, Chang PY, et al. Impact of comorbidity and age on determinants therapeutic strategies in advanced pancreatic head cancer patients with obstructive jaundices. Medicine (Baltimore). 2015;94:e1298.CrossRef

11.

Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and Leukemia Group B 9565. J Clin Oncol. 2000;18:2780–7.CrossRefPubMed

12.

Rothenberg ML, Meropol NJ, Poplin EA, Poplin EA, Van Cutsem E, Wadler S, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801–71.CrossRefPubMed

13.

Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol. 2013;24:1972–9.CrossRefPubMedPubMedCentral

14.

Oettle H, Riess H, Stieler JM, Heil G, Shwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423–9.CrossRefPubMed

15.

Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). J Clin Oncol. 2014;32:A4022.CrossRef

16.

Chen LT, Von Hoff DD, Li CP, Wang-Gillam A, Bodoky G, Dean AP, et al. Expanded analyses of napoli-1: phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol. 2015; 33 S3.

17.

Hosein PJ, de Lima G, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, et al. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol. 2013;36:151–6.CrossRefPubMed

18.

Bertocchi P, Abeni C, Meriggi F, Rota K, Rizzi A, Di Biasi B, Aroldi F, et al. Gemcitabine plus nab-paclitaxel as second-line and beyond treatment for metastatic pancreatic cancer: a single institution retrospective analysis. Rev Recent Clin Trials. 2015;10:142–5.CrossRefPubMed

19.

Petrelli F, Borgonovo K, Ghilardi M, Cabiddu M, Barni S. What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. Rev Recent Clin Trials. 2010;5:43–56.CrossRefPubMed

20.

Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii Saab TS. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology. 2009;76:333–7.CrossRefPubMed

21.

Demols A, Peeters M, Polus M. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer. 2006;94:481–5.CrossRefPubMedPubMedCentral

22.

Reni M, Cereda S, Mazza E, Passoni P. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol. 2008;31:145–50.CrossRefPubMed

23.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.CrossRefPubMed

24.

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.CrossRefPubMed

25.

Ducreaux M, AS Cuhna, Caramella C, Hollebecque A, Burtin D, Goéré D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;5:v56–68.CrossRef

26.

Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost. 2010;8:1702–92.CrossRefPubMed

27.

NCCN Guidelines for Myeloid Growth Factor. 2015. Version 2. http://www.tri-kobe.org/nccn/guideline/hematologic/english/myeloid_growth.pdf. Accessed Feb 2016.

28.

NCCN Guidelines for Antiemesis. 2015. Version 2. http://www.prolekare.cz/dokumenty/Antiemetikum_guidelines.pdf. Accessed Feb 2016.

29.

Di Maio M, Bria E, Banna GL, Puglisi F, Garssino MC, Lorusso DP. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. Anticancer Drugs. 2013;24:99–111.CrossRefPubMed

30.

Qi WX, Lin F, Sun YJ, Tang LN, Shen Z, Yao Y. Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis. Br J Clin Pharmacol. 2013;76:338–47.CrossRefPubMedPubMedCentral

31.

Giordiano G, Milella M, Lo Re G, Di Marco M, Melisi D, Passardi A, et al. Nab paclitaxel (Nab-P) and Gemcitabine (G) first line chemotherapy (CT) in metastatic pancreatic cancer (mPC) patients (pts) relapsed after adjuvant treatment (ADJ T): A “real life” study. J Clin Oncol. 2017;35(Suppl 4S):396. doi:10.1200/JCO.2017.35.4_suppl.396.

Titel: Pancreatic ductal adenocarcinoma: metastatic disease
verfasst von: A. J. Muñoz Martín
J. Adeva
J. Martínez-Galán
J. J. Reina
M. Hidalgo
Publikationsdatum: 16.06.2017
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1690-6

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Pancreatic ductal adenocarcinoma: metastatic disease

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2017

Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy

Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie